Elixinol Wellness Ltd · ASX:EXL
Elixinol Wellness — Elixinol Global — Investor Presentation (May 2019)
29 slides from Elixinol Wellness's investor presentation, May 21, 2019
Slide 1: Elixinol Global Limited Updated investor presentation May 2019
For personal use only Elixinol Global Limited Updated investor presentation May 2019 ASX: EXL, OTCQX: ELLXF | www.elixinolglobal.com
Slide 2: Disclaimer
Disclaimer For personal use only This presentation contains summary information about Elixinol Global Limited (EXL) and its subsidiaries and their activities. The information in this presentation does not purport to be complete. It should be read in conjunction with EXL’s other periodic and continuo
Slide 3: Agenda
For personal use only Agenda What is cannabis? 4 Who are Elixinol Global? 5 Key highlights 12 Growth drivers by business 15 Outlook 25 Q+A 28 www.elixinolglobal.com
Slide 4: What is cannabis?
Cannabis Who we Key Growth Outlook Q&A Q&A Appendix definition are highlights drivers For personal use only 4 EXL | Investor Presentation, May 2019
Slide 5: Who we are
For personal use only Who we are www.elixinolglobal.com
Slide 6: Board and management team
Cannabis Who we Key Growth Outlook Q&A Q&A Appendix definition are highlights drivers Board and management team Key market statistics* For personal use only Andrew Duff | Non-Executive Chairman Paul Benhaim1 | CEO / Executive Director Experienced ASX listed company director. Ex CFO Over 25 years’ ex
Slide 7: Corporate overview
Cannabis Who we Key Growth Outlook Q&A Q&A Appendix definition are highlights drivers Corporate overview For personal use only Key market Key statistics 1 market statistics* Share price history ASX: EXL OTCQX: ELLXF • IPO on ASX: 8 January 2018: raised A$20m at price of A$1.00 • September 2018: rais
Slide 8: Elixinol Global company description
Cannabis Who we Key Growth Outlook Q&A Q&A Appendix definition are highlights drivers For personal use only Elixinol Global (herein referred to as EXL) is a global consumer brand company with products in multiple cannabis verticals, including CBD-based supplements, skincare, hemp food and medical ca
Slide 9: Diversified portfolio
Cannabis Who we Key Growth Outlook Q&A Q&A Appendix definition are highlights drivers Diversified portfolio FY2018 revenue by business unit For personal use only Consumer Products Pharmaceutical Dietary Supplements Hemp Foods Medical Cannabis Revenue $32.5m (87%)* Revenue $4.9m (13%)* Seeking licens
Slide 10: Why we're different
Cannabis Who we Key Growth Outlook Q&A Q&A Appendix definition are highlights drivers Why we’re different For personal use only We believe our products represent the highest quality in the market • Highly diversified business model with multiple products sold through multiple sales channels • In-hou
Slide 11: Elixinol Global, international footprint
Cannabis Who we Key Growth Outlook Q&A Q&A Appendix definition are highlights drivers Elixinol Global, international footprint An established platform that can be leveraged for consumer products For personal use only Global platform for growth • Avenues to market established across • Operations (pin
Slide 12: Key highlights
For personal use only Key highlights www.elixinolglobal.com
Slide 13: FY2018 Key Highlights
Cannabis Who we Key Growth Outlook Q&A Q&A Appendix definition are highlights drivers FY2018 Key Highlights For personal use only Group revenue increased Strong balance sheet with net cash of 121% $42.7m EXL investing to build a to $37.1m driven by continued strong sales by Elixinol to drive interna
Slide 14: FY2019 Key Highlights
Cannabis Who we Key Growth Outlook Q&A Q&A Appendix definition are highlights drivers FY2019 Key Highlights Strong start with momentum building For personal use only First agreements signed with large European and US retail distributors Strategic investment EU & US National retailer distribution mad
Slide 15: Growth drivers by business
For personal use only Growth drivers by business www.elixinolglobal.com
Slide 16: Elixinol Global key growth initiatives
Cannabis Who we Key Growth Outlook Q&A Q&A Appendix definition are highlights drivers Elixinol Global key growth initiatives Continued disciplined approach to drive future revenue growth For personal use only 9 Increase distribution through US national retail chains (commenced April 2019) 9 Expansio
Slide 17: Revenue growth by Consumer Products segment
Cannabis Who we Key Growth Outlook Q&A Q&A Appendix definition are highlights drivers Revenue growth by Consumer Products segment Growth across all revenue segments with a clear strategy to drive higher margin products For personal use only Elixinol USA Hemp Foods Australia A$ million, 31 December y
Slide 18: Growth Drivers: Elixinol
Cannabis Who we Key Growth Outlook Q&A Q&A Appendix definition are highlights drivers Growth Drivers: Elixinol Firmly positioned to drive revenue growth and take CBD market share For personal use only • Doubling production capacity in the USA with new 12,000 sq. ft. square foot Colorado facility (on
Slide 19: Growth Drivers: Elixinol – US retailer agreements
Cannabis Who we Key Growth Outlook Q&A Q&A Appendix definition are highlights drivers Growth Drivers: Elixinol – US retailer agreements Strong interest from national retailers - first agreements signed and products being stocked For personal use only • Partnered with retail brokerage firm, Presence
Slide 20: Growth Drivers: Elixinol – Europe retailer agreements
Cannabis Who we Key Growth Outlook Q&A Q&A Appendix definition are highlights drivers Growth Drivers: Elixinol – Europe retailer agreements Strong interest from national retailers - first agreements signed and products being stocked For personal use only • Recently expanded sales teams in key centre
Slide 21: Growth Drivers: Elixinol – New York state CBD authorisation
Cannabis Who we Key Growth Outlook Q&A Q&A Appendix definition are highlights drivers Growth Drivers: Elixinol – New York state CBD authorisation Supplying quality product to major national retailers within a clear regulatory framework For personal use only • Elixinol is officially granted a coveted
Slide 22: Growth Drivers: Elixinol – Pet Releaf investment
Cannabis Who we Key Growth Outlook Q&A Q&A Appendix definition are highlights drivers Growth Drivers: Elixinol – Pet Releaf investment Strategic investment: 25% equity interest in Altmed Pets, LLC (Pet Releaf)* For personal use only • The most widely distributed hemp and CBD pet product in the marke
Slide 23: Growth Drivers: Hemp Foods Australia
Cannabis Who we Key Growth Outlook Q&A Q&A Appendix definition are highlights drivers Growth Drivers: Hemp Foods Australia Leveraging industry leading position in Australia to further accelerate growth For personal use only • Solidify #1 market position in Australia for hemp food branded • Launched
Slide 24: Growth Drivers: Nunyara Pharma (Australia)
Cannabis Who we Key Growth Outlook Q&A Q&A Appendix definition are highlights drivers Growth Drivers: Nunyara Pharma (Australia) Leveraging US cannabinoid production and formulation expertise for Medical Cannabis For personal use only Subject to ODC licenses and planning approvals: • Cultivate 5000m
Slide 25: Outlook
For personal use only Outlook www.elixinolglobal.com
Slide 26: Outlook
Cannabis Who we Key Growth Outlook Q&A Q&A Appendix definition are highlights drivers Outlook For personal use only EXL’s global investment into top line growth is on track. There is a significant opportunity to grow sales in the US via large national retailers, with ongoing conversations expected t
Slide 27: Strategic outlook: delivering on our corporate strategy
Cannabis Who we Key Growth Outlook Q&A Q&A Appendix definition are highlights drivers Strategic outlook: delivering on our corporate strategy Capturing substantial global growth opportunity in hemp-CBD and medical cannabis For personal use only FY2021 • Global top 3+ leadership FY2020 position in CB
Slide 28: Q&A
For personal use only Q&A www.elixinolglobal.com
Slide 29: For more information
For personal use only For more information: Investor relations and media please contact: Australia United States of America Glen Zurcher Cody Slach Account Director, IR Department Managing Director, Gateway Investor Relations IR@elixinolglobal.com | +61 420 249 299 USIR@elixinolglobal.com | +1 949 5